|
|
| Usman,Muhammad; Zhen-Han,Zhu; Ze-Na,Chang; Jun-Ping,Han; Wen,Qian; Chang-Qing,Yang; Miyu,Nishikawa; Toshiyuki,Sakaki. |
| Iguratimod (IGU, also known as T-614), a novel disease modifying antirheumatic drug intended to cure patients with rheumatoid arthritis (RA). The purpose of this study is to evaluate the effect of IGU on the pharmacokinetics of CYP2C9 probe drug diclofenac and its metabolite 4′-hydroxy diclofenac in vivo and in vitro. In in vivo experiments, 24 rats were randomly assigned to three groups consisting of the control group (Normal saline), low dose IGU group (10 mg/kg) and high dose IGU group (30 mg/kg). Blood samples were collected from orbital sinuses vein before 1 hour and serial times of giving diclofenac (15 mg/kg) to all the rats. Plasma concentration of diclofenac and its metabolite 4´-hydroxy diclofenac were assayed by high performance liquid... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Iguratimod/effects; Diclofenac/effects; 4-hydroxy diclofenac; CYP2C9/pharmacokinetics; Inhibitory. |
| Ano: 2019 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100523 |
| |
